Investment Thesis
Pre-revenue biopharmaceutical company with zero revenue and -$9.6M net loss in latest period. While balance sheet is strong with $31.7M cash and no debt providing ~3-4 years runway, ongoing cash burn with no product commercialization visibility creates significant execution risk. Company remains entirely dependent on successful drug development and commercialization for viability.
Strengths
- Strong cash position of $31.7M with zero long-term debt
- Excellent liquidity ratios (4.92x current ratio) provides operational flexibility
- Low liability burden ($7.5M) limits near-term financial distress risk
Risks
- Zero revenue with no clear path to commercialization or profitability
- Cash burn of -$9.6M per period with no offsetting revenue
- High development risk typical of pre-clinical/early-stage pharmaceutical companies
- Negative ROE (-31.5%) and ROA (-25.3%) reflect inefficient capital deployment
Key Metrics to Watch
- Monthly cash burn rate trend and projected runway
- Clinical trial progress and FDA milestone achievements
- Time to first revenue-generating product launch
Financial Metrics
Revenue
0.0
Net Income
-9.6M
EPS (Diluted)
$-1.11
Free Cash Flow
-9.6M
Total Assets
37.9M
Cash
31.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-31.5%
ROA
-25.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
4.92x
Quick Ratio
4.92x
Debt/Equity
0.00x
Debt/Assets
19.7%
Interest Coverage
-5,532.51x
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:55:53.421891 |
Data as of: 2026-03-31 |
Powered by Claude AI